# Phase I Trial HIPEC With Nal-irinotecan

> **NCT04088786** · PHASE1 · COMPLETED · sponsor: **Stony Brook University** · enrollment: 18 (actual)

## Conditions studied

- Peritoneal Cancer
- Pseudomyxoma Peritonei
- Mucinous Adenocarcinoma
- Mucinous Tumor
- Colorectal Cancer
- Gastric Cancer
- Primary Peritoneal Carcinoma
- Mesothelioma

## Interventions

- **DRUG:** nanoliposomal irinotecan

## Key facts

- **NCT ID:** NCT04088786
- **Lead sponsor:** Stony Brook University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-10-22
- **Primary completion:** 2021-10-11
- **Final completion:** 2022-04-14
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2022-05-06

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04088786

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04088786, "Phase I Trial HIPEC With Nal-irinotecan". Retrieved via AI Analytics 2026-06-06 from https://api.ai-analytics.org/clinical/NCT04088786. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*